Related Experiment Video
Updated: Apr 28, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Recent advances in antithrombotic treatment for acute coronary syndromes
James P Howard1, Sotiris Antoniou, Daniel A Jones
1Barts NIHR Cardiovascular Biomedical Research Unit, William Harvey Research Institute, Barts and The London Medical School, Queen Mary University, London, UK.
Insights
Anti-thrombotic drugs are crucial for acute coronary syndromes (ACS) and percutaneous coronary intervention. Modern therapies offer improved efficacy and safety through targeted drug development.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Anti-thrombotic therapy is central to managing acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI).
- Therapeutic strategies have significantly evolved since 1996, moving beyond aspirin and unfractionated heparin.
Purpose of the Study:
- To review the evolution of anti-thrombotic therapy in ACS and PCI.
- To highlight recent pharmacological advancements and novel agents.
Main Methods:
- Literature review of anti-thrombotic drug development and clinical guidelines.
- Analysis of therapeutic advancements in ACS management.
Main Results:
- Contemporary anti-thrombotic armamentarium for ACS reflects significant pharmacological progress.
- Newer agents focus on predictable efficacy, target specificity, and reduced inter-individual variability.
Conclusions:
- Modern pharmacotherapies aim to enhance treatment efficacy while minimizing complications in ACS and PCI.
- Targeted drug development represents a key trend in improving patient outcomes.
Abstract:
Anti-thrombotic drugs constitute the cornerstone of therapy in the management of acute coronary syndromes (ACS) and for patients undergoing percutaneous coronary intervention. Anti-thrombotic therapy during percutaneous coronary intervention for ACS has evolved substantially over the past 15 years. In the original 1996 ACC/AHA guidelines for the management of acute myocardial infarction (MI), only one antiplatelet agent (aspirin) and one anticoagulant (unfractionated heparin) were recommended as class I therapies. Much has since changed and the contemporary therapeutic armoury for the treatment of ACS reflects the pharmacological advances that have taken place. Recent developments in the medical management of ACS have been based around developing drugs with more predictable efficacy and at known drug targets. However there has also been considerable development of novel agents. New pharmacotherapies for ACS reflect efforts to improve efficacy and minimize complications by increasing target specificity and reducing inter-individual variation in therapeutic response.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome V: Nursing Management
Angina IV: Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins

